Peptide drug development looks very different today than it did a decade ago. Back then, most programs involved relatively straightforward linear sequences. Now, the molecules entering development pipelines are structurally ambitious. Cyclic peptides, lipidated analogs, stapled sequences, long-chain conjugates. With over 100 peptide drugs approved globally and more than 170 in active clinical trials, the bar for what a manufacturing partner needs to handle has moved significantly.

Most teams understand this in principle. Where things get complicated is in practice. The partner you choose for peptide synthesis influences more than just the manufacturing step. It shapes your regulatory timeline, your CMC documentation, and whether you reach commercial supply without expensive rework. Get the selection wrong and you find out at the worst possible moment.

Complex Molecules Reveal What Generalist Manufacturers Cannot Do

There is a version of peptide synthesis that most CDMOs can handle. Short, linear sequences with standard amino acids, standard resin chemistry, standard purification. That version is not what most innovative programs require anymore.

The structural features that drive complexity include:

• Long chains above 30 amino acids, where cumulative coupling failure builds with every residue added
• On-resin aggregation, where peptide chains self-associate mid-synthesis, blocking further coupling entirely
• Disulfide-bridged and cyclic peptides, which require controlled oxidation conditions and regioselective bond formation
• Lipidated and PEGylated sequences, where conjugation chemistry adds a separate layer of purification and analytical difficulty

A peptide synthesis company will have worked through each of these challenges before, ideally with batch data to show for it. General platform access is not the same as demonstrated experience on molecules with two or more of these risk factors combined.

Choosing the Right Synthesis Route Is Not a Technical Formality

Most manufacturers default to solid phase peptide synthesis (SPPS) because it is what they know. That default is a risk for programs where SPPS is not the best fit.

The three main routes carry meaningfully different trade-offs.

SPPS works well for short to medium sequences. It is widely available, but at commercial scale, the process mass intensity climbs steeply. Solvent and reagent consumption becomes a significant cost and sustainability issue.

Liquid phase peptide synthesis (LPPS) suits longer sequences better. It allows intermediate isolation and characterization at each fragment stage, which improves visibility into the process and often delivers better economics at scale.

Hybrid approaches use fragment condensation to reduce cumulative failure modes in longer chains while keeping overall yield competitive. For complex molecules, this can be the most defensible route from both a technical and regulatory standpoint.

Working with the right CDMO for peptide manufacturing means having a partner who evaluates route selection against your actual sequence characteristics, your target scale, and what purification will require downstream. Not one who selects a route before that analysis has been done.

Purification Is Where Synthesis Quality Shows Up

A synthesis process that looks clean at the crude stage can still produce a final drug substance that fails specification. The impurities generated in peptide synthesis are not easy to remove. Deletion sequences, epimers, oxidation variants, and aspartimide byproducts are structurally near-identical to the target molecule. Standard reverse-phase HPLC frequently cannot resolve them.

What a capable purification team brings to the program

• Orthogonal analytical methods, including LC-MS and high-resolution mass spectrometry, to identify and characterize every peptide-specific impurity in the crude
• Preparative chromatography infrastructure scaled to the program’s commercial requirements, not just development batches
• Counterion management, including validated TFA removal protocols and pharmaceutically acceptable salt form selection before any regulatory submission

The most reliable outcomes come from programs where purification strategy is designed alongside synthesis, not added afterward when problems appear. This is a design decision, and it has to be made early.

Regulatory Readiness Is Built In, Not Bolted On

A peptide synthesis partner that delivers GMP batches without CMC support is only solving part of the problem.

The EMA synthetic peptide guideline, effective June 2026, introduces specific documentation requirements around manufacturing routes, impurity types including stereoisomers and deletion sequences, pooling strategy in preparative chromatography, and comparability. FDA expectations on impurity profiling for ANDA submissions are tightening in parallel.

What to verify in any potential partner

• Direct experience authoring Drug Master Files for peptide APIs, not small molecule CMC documentation adapted for peptides
• Impurity profiling methods aligned to current EMA and FDA guidance
• Comparability data packages that support process changes between development phases without forcing full revalidation

Teams that build this documentation correctly from Phase I carry a meaningfully lighter burden through every subsequent filing. Those who retrofit it later spend time and budget they did not plan for.

Switching Partners Mid-Program Has a Real Cost

A full technology transfer typically takes 12 to 18 months. It involves engineering batches, method revalidation, and updated regulatory documentation. For a program approaching NDA or MAA submission, that timeline has direct revenue consequences.

The more common scenario is subtler. A CDMO handles clinical-stage synthesis competently but lacks the infrastructure and analytical depth needed at commercial scale. That gap usually surfaces during scale-up validation or pre-approval inspection, both of which are very late in the development timeline to discover it.

This is why partner selection at the development stage matters more than it might appear. The decision compounds in either direction.

Conclusion

Peptide synthesis reliability at commercial scale is not a single capability. It is synthesis expertise, purification depth, analytical infrastructure, and regulatory experience working as one integrated program. A gap in any one of these areas eventually affects the others.

Neuland Laboratories supports peptide programs from early process development through commercial GMP supply, with capabilities across SPPS, LPPS, and hybrid synthesis platforms, a team of 50-plus peptide scientists, and a new commercial facility adding 6,370 L of reactor capacity at Bonthapally in 2026.

For teams with a peptide program in development, contact Neuland’s team to discuss your synthesis and scale-up requirements.

FAQs

1. What should pharma teams look for when evaluating a peptide synthesis partner?

Look for demonstrated experience with your specific peptide class. Cyclic, lipidated, disulfide-bridged, and conjugated peptides each require distinct synthesis and analytical approaches. Verify that the partner has purification infrastructure matched to your target scale, and that their regulatory team has authored peptide-specific CMC documentation, not small molecule dossiers adapted for peptides.

2. Why does synthesis route selection matter so much for peptide programs?

SPPS, LPPS, and hybrid routes carry different cost, yield, and impurity profiles that become more pronounced as batch size increases. Choosing the wrong route at development stage forces process redesign mid-program, which is expensive and time-consuming. The right choice depends on sequence length, structural complexity, target scale, and what downstream purification will realistically require.

3. When is the right time to bring in a peptide synthesis partner?

Early in process development, ideally before IND filing. Partners engaged at this stage can influence route selection, build the analytical package correctly from the first batch, and structure CMC documentation for the full development lifecycle. Engaging a partner after clinical-scale batches are already established significantly increases the risk and cost of any future technology transfer.

4. How does the new EMA synthetic peptide guideline affect manufacturers and sponsors?

The guideline, effective June 2026, sets specific requirements around manufacturing routes, peptide-specific impurity characterization, preparative chromatography pooling strategy, and comparability documentation. Sponsors whose CMC packages were built on generic API frameworks will likely need to revise their documentation. Partners who have already worked within these requirements will be able to move faster and with fewer surprises during regulatory review.